KRAS and neoplasm: Currently, it is recommended to specifically test for potentially actionable somatic findings including, but not limited to, fusions (ALK, NRG1, NTRK, ROS1, FGFR2, and RET), mutations (BRAF, BRCA1/2, KRAS, and PALB2), amplifications (HER2), microsatellite instability (MSI), mismatch repair deficiency (dMMR), and tumor mutational burden via an FDA-approved and/or validated next-generation sequencing (NGS)-based assay [8].